New research demonstrates that a commonly studied anti-aging drug combination produces severe myelin loss in laboratory mice—a finding that exceeded researchers’ initial safety predictions. The neurological damage observed was substantially more pronounced than anticipated, with treated animals displaying marked cognitive impairments and cellular changes characteristic of demyelinating diseases.
Myelin, the critical insulating material surrounding nerve fibers, showed significant deterioration in treated subjects. This substantial damage raises immediate questions about the translational safety of such compounds for human populations. The severity of neurological effects documented in this preclinical model suggests that current anti-aging drug candidates may carry unrecognized risks that warrant careful reassessment before human clinical development proceeds.
These findings highlight the importance of rigorous safety monitoring in longevity research. Read the full article on GMJ Newsroom.
Was this article helpful?
